But the evidence is uneven, the effects are modest compared to pharmaceutical GLP-1 receptor agonists, and a lot of what gets marketed as a natural Ozempic alternative doesnt hold up to scrutiny
( In drug repositioning it is crucial to understand the disease-drug relationship, for this reason, there are several approaches to address the problem: In silico approaches: in this type of approach, various public databases, clinical trials, and bioinformatic systems are used to identify drug-target interactions ( Cluster approaches tend to find new drug-target or drug-disease relationships (Parisi et al., 2020)
Brighten breaks down how perimenopause and menopause shift insulin sensitivity, fat distribution, appetite, and recovery and where glucagon-like peptide-1 (GLP-1) receptor agonists (think semaglutide/Ozempic, Wegovy, liraglutide, tirzepatide as a related incretin therapy) can fit safely alongside hormone therapy, lifting, protein, and smart lab work
It is FDA-approved to treat adults with type 2 diabetes when used along with diet and exercise
Some patients are unable to continue long-term therapy because insurance coverage varies greatly even in developed markets
Liraglutide 3 mg (Saxenda, FDA-approved for weight management), an earlier-generation daily GLP-1 injection, demonstrates similar gastrointestinal side effect patterns with diarrhea reported in approximately 21% of patients according to its FDA label
Draadborstels"" loading="lazy"/>
